Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia - Full Text View

Sponsored by:	National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00867269

Purpose

Background:

Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocytes (a type of white blood cell), which can lead to opportunistic infections or autoimmune disorders and diseases.

Objectives:

To characterize the natural history with regard to CD4+ T cell count and onset of infection, malignancy, and autoimmunity.
To describe the immunological status of patients affected by ICL while providing the best possible standard therapy to eradicate opportunistic infections.
To establish the timeline of CD4 lymphocytopenia, with particular focus on defining subgroups of patients according to the decline, stabilization, or rise of CD4+ T cell counts over time.
To characterize the opportunistic infections that occur in ICL patients at microbiologic and molecular levels.
To characterize the immunophenotype and possible genetic immunodeficiency causes of ICL.
To determine whether measurable immunologic parameters correlate with the development of opportunistic infections or other comorbidities such as lymphoma in patients with ICL.
To determine whether there is any association between ICL and autoimmunity.
To determine CD4+ T cell turnover, survival, functionality, and cytokine responsiveness in ICL patients.

Eligibility:

Patients 2 years of age and older with an absolute CD4 count less than 300 in children 6 years or older and adults or less than 20% of T cells in children younger than 6 on two occasions at least 6 weeks apart.
Patients with negative results of HIV testing by ELISA, Western Blot, and viral load.
Patients must not have underlying immunodeficiency conditions, be receiving cytotoxic chemotherapy (anti-cancer drugs that kill cells), or have cancer.

Design:

At the initial visit to the National Institutes of Health, the following evaluations will be conducted:
Personal and family medical histories.
Physical examination, including rheumatology evaluation and other consultations as medically indicated (e.g., dermatology, pulmonology, ophthalmology, imaging studies).
Blood samples for analysis of red and white blood cell counts, liver function, immune hormones, and antibody and autoantibody levels, white blood cell growth and function, and DNA.
Urinalysis and urine pregnancy testing for female patients of childbearing age.
Evaluation and treatment of active infectio...

Condition
Idiopathic CD4+ Lymphocytopenia Cryptococcal Meningitis Warts

Study Type:	Observational
Study Design:	Prospective
Official Title:	Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

Resource links provided by NLM:

MedlinePlus related topics: Autoimmune Diseases Meningitis Warts

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:	100
Study Start Date:	March 2009
Estimated Primary Completion Date:	February 2019 (Final data collection date for primary outcome measure)

Detailed Description:

Idiopathic CD4+ lymphocytopenia (ICL) is a disorder characterized by decreased numbers of circulating CD4+ T lymphocytes in the absence of known causes of CD4+ lymphocytopenia. ICL is defined as an absolute CD4+ T cell count of less than 300 cells/mL in a patient with no human immunodeficiency virus infection or known immunodeficiency syndrome. The causes and frequency of the disorder remain unknown. The condition is typically diagnosed when patients present with a serious infection. In this natural history protocol, we will evaluate patients with CD4+ T cell counts below 300 cells/microL. We propose to follow 100 patients for a minimum of 4 and maximum of 10 years, with a particular focus on the association between ICL and autoimmune disease. We will collect blood for immunologic, rheumatologic, and genetic testing in an effort to identify and understand the underlying defects that cause ICL and follow its course in a cohort of patients who will receive best standard therapy for opportunistic infections.

Eligibility

Ages Eligible for Study:	2 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA:

To be eligible for this study, patients must satisfy all of the following inclusion criteria:

Age greater than or equal to 2 years
Absolute CD4 count < 300 cells/microL or < 20% of total T cells in children greater than or equal to 6 years old and adults on at least two occasions at least 6 weeks apart; or CD4+ percentage < 20% of normal on 2 occasions at least 6 weeks apart in children < 6 years old
Ongoing care by a referring primary care physician
Willingness to allow storage of blood and tissue samples for future analysis

EXCLUSION CRITERIA:

Patients will be ineligible for this study if they satisfy any of the following criteria:

Infection with HIV-1, HIV-2, or human T-cell lymphotropic viruses (HTLV-1 or HTLV-2) as demonstrated by ELISA and Western blot and/or viral load testing
Known underlying immunodeficiency syndrome
Evidence of active malignancy
Receipt of medications, herbal substances, or biologic agents known to diminish the CD4+ count within 30 days of when the CD4+ lymphocytopenia was detected
Any condition that in the judgment of the investigators would place the subject at undue risk or compromise the results of the study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00867269

Contacts

Contact: Patient Recruitment and Public Liaison Office	(800) 411-1222	prpl@mail.cc.nih.gov
Contact: TTY	1-866-411-1010

Locations

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike	Recruiting
Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

More Information

Additional Information:

NIH Clinical Center Detailed Web Page This link exits the ClinicalTrials.gov site

Publications:

Fauci AS. CD4+ T-lymphocytopenia without HIV infection--no lights, no camera, just facts. N Engl J Med. 1993 Feb 11;328(6):429-31. No abstract available.

Laurence J, Siegal FP, Schattner E, Gelman IH, Morse S. Acquired immunodeficiency without evidence of infection with human immunodeficiency virus types 1 and 2. Lancet. 1992 Aug 1;340(8814):273-4.

Ho DD, Cao Y, Zhu T, Farthing C, Wang N, Gu G, Schooley RT, Daar ES. Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection. N Engl J Med. 1993 Feb 11;328(6):380-5.

Study ID Numbers:	090102, 09-I-0102
Study First Received:	March 20, 2009
Last Updated:	August 24, 2009
ClinicalTrials.gov Identifier:	NCT00867269 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Idiopathic Lymphocytopenia
Opportunistic Infection
Immunodeficiency Syndrome

Autoimmune Disease
CD4+ Lymphocytes
Idiopathic CD4 Lymphocytopenia

Study placed in the following topic categories:

Opportunistic Infections
Meningitis, Fungal
Autoimmune Diseases
Hematologic Diseases
Lymphopenia
Central Nervous System Diseases
Leukocyte Disorders
Immunologic Deficiency Syndromes
Meningitis

Absent T Lymphocytes
Mycoses
Warts
Central Nervous System Infections
Meningitis, Cryptococcal
Central Nervous System Fungal Infections
Leukopenia
Cryptococcosis

Additional relevant MeSH terms:

Meningitis, Fungal
Immune System Diseases
Hematologic Diseases
Nervous System Diseases
Lymphopenia
Central Nervous System Diseases
Leukocyte Disorders
Immunologic Deficiency Syndromes

Meningitis
Mycoses
Central Nervous System Infections
Meningitis, Cryptococcal
Central Nervous System Fungal Infections
Leukopenia
Cryptococcosis

ClinicalTrials.gov processed this record on August 25, 2009